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Abstract
Introduction: The aim of this study is to examine whether moderate hiperhomocysteinemia is an independent risk fac-
tor for cerebral infarction. 
Methods: We have measured homocysteine levels in 50 patients with ischemic stroke during acute phase and post-
acute phase, 50 patients diagnosed with vascular dementia and healthy group of 50 subjects. Homocysteine concentra-
tion in serum was measured, on the basis of ] uorescent polarisation measuring. 
Results: The study demonstrated that homocysteine concentration was 16.93 ^ mol/L in the patient group with ischemic 
stroke, and in the group of patients with vascular dementia was 20.39 ^mol/L. Homocysteine increases during the post-
acute phase of ischemic stroke after 7 days for 1.54 ^mol/L and 14 days for 3.66 ^mol/L compared to the concentration 
of homocysteine after the  rst hours of hospitalization. Using Wilcoxon signed ranks and Mann-Whitney (P < 0.05) tests 
we got signi cant difference between homocysteine concentration at acute phase and post-acute phase of ischemic 
stroke and it was signi cant difference between concentrations of homocysteine in the acute and post-acute phase of 
ischemic stroke and vascular dementia. The Spearman correlation test was found signi cant correlation between the 
number of strokes and the concentration of homocysteine in serum of patients with vascular dementia. 
Conclusions: The homocysteine concentration rises signi cantly during of acute phase of ischemic brain stroke, and 
it is signi cantly increased during post-acute phase, which is a predictor factor for further development of vascular de-
mentia, or a new ischemic brain stroke. 
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Introduction
Th e ischemic stroke (IS) is major cause of global disa-
bility and is the second most common cause of death 
worldwide. Elevated tolal plasma homocysteine level 
is common in the old age and is well-established risk 
factor for cardiovascular and cerebrovascular disea-
se (1). Th e amino acid homocysteine occurs by de-
methylation of methionine, essential amino acid, which 
in enters the human body with food. It is found in 
the plasma mainly in the oxidized state (homocystei-
ne or homocysteine-cysteine disulfi de) and bound to 
proteins, mostly albumin (2,3). It was fi rst described 
in work of Butz and Vigneaud who have synthesized 
amino acid homocysteine in a reaction of strong con-
centrated acid with methionine. (4). Based on fi ndings 
observed in patients with homocystinuria, McCully 
postulated that hyperhomocysteinemia may play a 
role in the pathogenesis of atherotrombotic vascular 
disease (5). Elevated levels of homocysteine can there-
fore cause damage to several key pathways in the cen-
tral nervous system, either directly or by changing the 
methylation potential. Th e hyperhomocysteinemia is 
very common in patients with stroke and is suggested 
to be an independent risk factor for the disease (6,7). 
Th e elevated concentrations of homocysteine are respon-
sible for occurrence of atherosclerosis in at least 3 ways: 
1) toxic eff ect of homocysteine in endothelium of arte-
ries, 2) interference of homocysteine with clotting fac-
tors and 3) oxidation of low-density lipoprotein (LDL).
Although there are data on homocysteine metabolism, 
the pathogenesis of hyperhomocysteinemia is still not 
clear. Homocysteine is turned into a methionine by 
remethylation; methyl group donor in most tissues is 
5-methyltetrahydrofolate, nevertheless betaine is do-
nor in the liver, kidney and eye lens. Th e reaction is 
catalyzed by methionine-synthase (MS) with vitamin 
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B12 as a cofactor. Tetrahydrofolate incurred converts to 
5,10-methyl-tetrahydrofolate with the enzyme methyle-
ne-tetrahydrofolate reductase (MTHFR) and then in 
5-methyl-tetrahydrofolate. Another pathway of ho-
mocysteine metabolism is trans-sulphuration pathway 
in which homocysteine with serine turns to cystathioni-
ne under the action of enzymes cistationine-β-synthase 
(CBS) and cofactor vitamin B6. Aft er that cystathionine 
goes into cysteine under the infl uence of the enzyme 
γ-cystathionase (GCT) (8-10). Homocysteine metaboli-
sm is regulated by the concentration of methionine that 
is normally used for protein synthesis and synthesis of 
S-adenosyl-methionine. Homocysteine lies at the inter-
section two of metabolic pathways, transsulphuration 
pathway and remethylation cycle. Current availability 
of methionine determines the pathway by which the 
homocystein will be metabolized. Decrease of folic acid 
and vitamin B12 leads to increase of homocysteine and 
decreases the remethylation of homocysteine (11,12). 
It could be postulated that elevated total homocysteine 
is a risk factor for atherotrombic stroke in particular. 
Moreover, there is a debate whether homocysteine is a 
causative risk factor in stroke and myocard infarction or 
is merely a secondary marker of risk in survivors (13). 
Date regarding to homocysteine concentration imme-
diately aft er stroke would help to resolve this question, 
because the observation of a raised homocysteine at 
this time would be more suggestive of a causal asso-
ciation that the occurrence of hyperhomocysteinemia 
in survivous sampled at a time distant from the event.
Methods
Patients
Th e investigation included 100 patients and 50 healthy 
subjects. 250 blood samples were collected during 2008 
and 2009. All investigation was done respecting ethi-
cal standards by the Helsinki Declaration. Th e patients 
were hospitalised at Clinic of Neurology, Clinical Cen-
tre University of Sarajevo, Old home "Nedžarići, and 
Old home "Ernest Grin". Th e patients group included 
patients with fi rst ischemic stroke (50 subjects) and 
vascular dementia (50 subjects). Th e control group 
included 50 healthy subjects who were protégé at Old 
home "Nedžarići”. Criteria for inclusion of patients 
with stroke and vascular dementia were: diagnosis of 
fi rst ischemic stroke determined by computerized to-
mography (CT), presence of vascular dementia identi-
fi ed using computerized tomography (CT) and nuclear 
magnetic resonance (NMR), “Hachinski ischemic score“ 
grater or equal to 7 for patients with vascular dementia, 
age over 65 years for both sexes, two weeks of hospi-
tal stay for patients with ischemic stroke, stroke in pa-
tients with vascular dementia in last three to six years. 
Th e study inclusion criteria for control group were: 
excluded ischemic stroke or vascular dementia by 
computed tomography (CT) and nuclear magne-
tic resonance (NMR), age over 65 years for both 
sexes, excluded kidney, heart or vascular diseases.
Criteria for exclusion from the study, for both patients 
and controls, were: diseases that are associated with im-
paired renal function and renal failure (determined by 
serum creatinine concentration), chronic infl ammatory 
disease, rheumatoid arthritis, SLE, multiple sclerosis and 
psoriasis, acute lymphoblastic leukaemia, intestinal dis-
orders atrophic gastritis, Crohn's disease and ulcerative 
colitis, Hypothyroidism, patients on treatment with met-
hotrexat, carbamazepine, phenytoin, and theophylline.
Th e blood samples were collected at the mornings befo-
re the fi rst meal. For the group of 50 patients diagnosed 
with the fi rst ischemic brain stroke, blood samples were 
taken during the acute phase (initial 24-48 hospitaliza-
tion hours), and post-acute phase (aft er 7±1 days, and 
aft er 11-14 hospitalization days). For the group of 50 
patients diagnosed with vascular dementia developed 
as a consequence of ischemic brain stroke, i.e. of many 
small ischemic focus of various age. Th e study included 
27 men and 23 women in control group. Th ere were 
27 males and 23 females in the group with ischemic 
stroke and 28 men and 22 women in the group with 
vascular dementia. By analyzing the history of disease 
we collected data about radiological examinations of 
brain computed tomography (CT) and brain nucle-
ar magnetic resonance (NMR). 92% (46) of patients 
suff ering from ischemic stroke had the diagnosis ICV 
per trombosim and at 8% (4) patients the diagnosis was 
ICV per emboliam. Level of albumin was obtained from 
patients history and was in normal range (35-50g/L). 
Th e value of serum homocysteine concentration was 
determined using AxSYM (Abbott), based on mea-
surements of fl uorescence polarization immunoassay 
(FPIA) technology. Th e reaction principle is conversi-
on of homocystine, mixed disulfi de and protein-bound 
forms of homocysteine in the sample to form of free 
homocysteine by the use of dithiothreitol (DTT). Aft er 
that, free homocysteine is converted to S-adenosyl-L-
homocysteine (SAH). Under physiological conditions, 
SAH hydrolases convert SAH to homocysteine. Levels 
of L-homocysteine are determined in human serum. 
Normal homocysteine concentration in serum is 3.36-
20.44 μmol/L for women and 5.90-16 μmol/L for men. 
Th e creatinin was determined using automatic analyzer 
Dimension (Dade Behring). Method for determination 
of creatinine is a modifi cation of the kinetic reaction of 
Jaff ee. Th e reference value for serum creatinine concen-
tration is 45-115 μmol/ L. Th e patient samples of blo-
od were collected in serum separation Vacutainer test 
tubes (Beckton Dickinson, Rutherford, NJ 07,070 U.S.) 
in volume of 3.5 mL. We used test tubes with gel. Aft er 
collection, samples were placed in ice and, aft er 30 to 60 
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minutes serum samples were obtained by centrifugation 
at 3000 rpm using centrifuge (Sigma 4-10). Aft er cen-
trifuging, concentration of homocysteine and creatinine 
in sera were determined. All subjects (patients and con-
trols) had concentration of creatinine in reference values.
Statistical analysis
Th e results were statistically analyzed using SPSS 
version 11 and Microsoft  Offi  ce Excel 2003. Avera-
ge values (χ), standard deviation (SD) and Spear-
man correlation coeffi  cient (r) were calculated, as 
well as Wilcoxon signed ranks and Mann-Whitney 
test with statistical signifi cance level of 0.05 (P <0.05).
Results
Th e average age in the control group was 69.34 years. In 
the group with vascular dementia, the average age was 
73.74 years. Th e group with ischemic stroke had an ave-
rage age of 70.12 years.
Mean concentrations of homocysteine in pati-
ents aft er ischemic stroke (24-48 hours, 7 days 
and 14 days), patients with vascular demen-
tia and control groups are shown in Table 1.
Th e average concentration of homocysteine and + 
/ - SD in patients aft er ischemic stroke (24-48 hours, 
7 days and 14 days), patients with vascular dementia 
and control groups are graphically show in Figure 1. 
Th e homocysteine serum concentrations were increa-
sed during the acute phase to the post acute phase of 
ischemic stroke, as shown by results in Figure 2. During 
hospitalization serum concentrations of homocysteine 
increased aft er seven days and then increased signifi -
cantly aft er the fourteenth day. In the acute phase aft er 
7 days of hospital treatment homocysteine concentrati-
on was increased for 1.54 μmol/L, aft er 14 days for 3.66 
μmol/L compared to the concentration aft er the fi rst 24-
48 hours. Between 7 and 14 days of treatment the con-
centration of homocysteine increases for 2.12 μmol / L.
Analysis of distribution showed assimetrical dis-
tribution of homocysteine levels in patients with 
ischemic stroke, vascular dementia and control 
group. We used Wilcoxon signed ranks for compa-
rison of serum homocysteine concentration in pati-
ents with ischemic brain stroke during acute phase 
and post-acute phase. Results are shown in Table 2. 
In Table 2. Z and P values of average serum homocystei-
ne concentrations in patients during acute and post-acu-
te phase of ischemic stroke are shown. Using Wilcoxon 
signed ranks test we have concluded that the average 
Patients with ischemic 
brain stroke
Patients with ischemic 
brain stroke
Patients with ischemic 
brain stroke
Patients with vascular 
dementia Control group
Time of determination 24-48 hours 7 days 14 days - -
Xsr 13.27 14.81 16.93 20.39 10.49
S.D. 5.62 6.03 7.63 10.15 1.92
S.E. 0.79 0.85 1.07 1.43 0.27
Number of patients 50 50 50 50 50
TABLE 1.  Serum concentration of homocysteine (Hcy) at patients with ischemic brain stroke, vascular dementia and control group.
FIGURE 1.  The mean serum homocysteine concentration +/- 
S.D in risk of patients (ischemic stroke (IS), vascular dementia) 
and control group
FIGURE 2.  Serum concentration of homocysteine in patient with 
ischemic stroke during  acute phase and post-acute phase.
(after 7 days) 
with (24-48 hours)
(after 14 days) 
with (24-48 hours)
(after 14 days) 
with (after 7 days)
Z -5.850 -6.1543 -5.927
P 0.000* 0.000* 0.000*
TABLE 2.  Comparison of serum homocysteine concentration 
(Hcy) in patients with ischemic brain stroke during  acute phase 
and post-acute phase
* P < 0.05 (Wilcoxon signed ranks) 
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serum homocysteine concentration 24-48 hours aft er 
the fi rst symptoms of ischemic stroke were signifi cantly 
diff ered from the concentration of homocysteine aft er 
7 and 14 days of hospital treatment (p < 0.05). Th ere 
was a signifi cant diff erence between the average ho-
mocysteine concentration aft er 7 and 14 days of hos-
pital treatment (p<0.05). Using Mann-Whitney U-test 
we made comparison of serum homocysteine between 
risk groups (ischemic stroke, vascular dementia) and 
control healthy group, the results are shown in Table 3. 
According to Mann-Whitney test for α = 5%, the diff e-
rence between concentrations of homocysteine in the 
acute phase of ischemic stroke and control healthy 
groups is not signifi cant. Th e same test for α = 5% has 
shown a signifi cant diff erence between concentrations 
of homocysteine in the acute phase of ischemic stro-
ke and control group. Th e serum concentrations of 
homocysteine increase aft er 7 days and signifi cantly 
increased aft er 14 days of hospital treatment. We fo-
und signifi cant diff erence between concentrations of 
homocysteine in the acute and the post-acute phase 
of ischemic stroke and a group with vascular demen-
tia (p<0.05). Th e concentration of serum homocystei-
ne concentration was higher in the group with vascu-
lar dementia than in the group with ischemic stroke. 
Average serum concentrations of homocysteine in the 
group with vascular dementia was signifi cantly diff e-
rent from control healthy group (p <0.05). Th e serum 
creatinene concentration was in reference value (45-115 
μmol/ L) for all patients in risk groups and in control 
group. So we can exclude that serum concentration of 
homocysteine was increased for kidney demage. In the 
group of patients with vascular dementia, 52% (26 pati-
ents) had an extensive one stroke, 32% (16 patients) two 
strokes, 16% (8 patients), many small ischemic focus 
without ischemic stroke the results are shown in Figu-
re 3. According to the Spearman correlation test, it was 
found a statistically signifi cant correlation between the 
number of strokes and concentrations of homocyste-
ine in the serum of patients with vascular dementia 
of p <0.05 (correlation coeffi  cient = 0.341, p = 0.015).
Th e serum homocysteine concentration is increasing with 
number of strokes infarctions and more ischemic focus. 
Discussion
Homocysteine is an independent risk factor for develo-
ping peripheral vascular, cerebrovascular and coronary 
heart disease. Th e mechanism by which the total ho-
mocysteine may cause vascular disease includes throm-
bosis, endothelial dysfunction and increased oxidation 
of LDH (low density cholesterol) (15). About 50% of 
patients with hyperhomocysteinemia have vascular 
changes before ther thirty years of old (16). Our study 
showed that the group of patients with ischemic stro-
ke 30% (15 patients) had moderate hyperhomocyste-
inemia, from the total sample number it was 44 % of 
men and 13% of woman. Th e results of our study have 
shown that the mean concentration of homocysteine af-
ter 24- 48 hours of hospital treatment was 13.27 μmol/L, 
aft er 7 days 14.81 μmol/L and 14 day 16.93 μmol/L in 
comparison to serum concentration in control group 
it was 10.49 μmol/L (Table 1). At the post-acute phase 
of ischemic stroke aft er 7 days homocysteine increces 
for 1.54 μmol/L in compared to the concentration of 
homocysteine aft er the fi rst 24-48 hours of patients hos-
pitalization. In our study, aft er 14 days of hospitalization 
of patients with ischemic stroke average homocystei-
ne concentration was increased from 0.20 μmol/L to 
20.42 μmol/L (average 3.66 μmol/L). Th e mean serum 
homocysteine concentration increases during fi rst to 
second week for 2.12 μmol/L. Th e results are shown in 
Figure 1 and Figure 2. In a two retrospective studies, the 
British regional health study and the Framingham He-
art Study, that there is independent association betwe-
Comparison groups Time of deter-mination
Mann-
Whitney U Z P
Ischemic brain stroke 
with control group 24-48 hours 1046.00 -1.406 0.160
Ischemic brain stroke 
with control group 7 days      696.50 -3.816 0.000*
Ischemic brain stroke 
with control group 14 days      335.50 -6.605 0.000*
ischemic brain stroke 
with vascular dementia 24-48 hours      486.00 -5.267 0.000*
ischemic brain stroke 
with vascular dementia 7 days     614.50 -4.381 0.000*
ischemic brain stroke 
with vascular dementia 14 days     790.50 -3.168 0.002*
vascular dementia 
with control group     44.000 -8.314 0.000*
TABLE 3.  Comparison of serum homocysteine concentration 
(Hcy) in risk group of patients with control group
* P < 0.05 (Mann-Whitney U-test )
FIGURE 3.  Number of brain attacks in patients with vascular de-
mentia. (0- many) small focus i without ischemic stroke (16 %), 
1- one ischemic stroke  (52 %) , 2- ischemic stroke (16 %)
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en serum homocysteine and the incidence of ischemic 
stroke if homocysteine concentrations were equal or 
greater than 15.4 μmol/L and homocysteine concentra-
tions were equal or greater than 14.24 μmol/L. In the 
Rotterdam study it is showed a signifi cant increase in 
stroke risk with increasing serum homocysteine levels 
above 18.6 μmol/L (17). High concentrations of ho-
mocysteine are closely correlated with the risk of silent 
stroke (18). It was concluded that homocysteine is an 
independent risk factor for stroke in people older than 
sixty years, and homocysteine concentrations above 
14 μmol/L increased to 80% risk of stroke (19). If the 
concentration of serum homocysteine increases for 1 
μmol/L the risk for new ischemic stroke increases for 
22% (20). Th e increase of homocysteine concentration 
for 5 μmol/Lincreased the risk for coronary heart disea-
se 1.6 times for men and 1.8 times for women, and cere-
brovascular disease increases the risk for both sexes 1.5 
times (21). It is believed that during the fi rst week aft er 
ischemic stroke homocysteine concentration increases 
for about 10% (22). Our research has shown that during 
the fi rst week aft er ischemic stroke, homocysteine con-
centration increases for about 11.6%. Using Wilcoxon 
signed ranks the mean value of serum homocysteine 
in patients with ischemic stroke aft er 24-48 hours was 
signifi cantly diff erent than the mean values of ho-
mocysteine aft er 7 and 14 days of patients hospitalisa-
tion with signifi cance of p < 0.05. Our result have show 
using same test that there was a signifi cant diff erence 
between the average homocysteine concentration aft er 
7 and 14 days of hospital treatment (p < 0.05) (Table 2). 
According to our results using the Mann-Whitney test 
average concentrations of homocysteine in the acute 
phase of ischemic stroke aft er 24-48 hours showed no 
signifi cant diff erence with control group. A signifi cant 
increase in homocysteine concentration occurs only in 
the acute phase in which there was a signifi cant diff e-
rence compared to the control group (Table 3). Th e re-
sults have shown that it is evident that the concentrati-
on of serum homocysteine increase aft er stroke. Th ere 
are two possible explanations for the change in serum 
homocysteine concentration aft er acute phase and du-
ring the pos-tacute phase of ischemic stroke recovery: 
• Th e acute phase of ischemic stroke following 
stress which leads to short-term decrease in 
serum homocysteine. Damage to cerebral ti-
ssue increases the production of oxygen ra-
dicals, increases oxidative stress, leading to 
possible subsequent changes in the degree of 
elimination of thiols, including homocysteine. 
• Serum homocysteine increases aft er the acute phase 
of ischemic stroke as a reason of folate and vitamins 
B6 or B12 defi ciency which is particularly common in 
elderly people. Impairment of renal function also le-
ads to increased concentrations of homocysteine (23). 
Th erefore, we excluded from our study patients with a 
high concentration of creatinine. Th e fi rst early signs of 
dementia are presented with a reduction in the volume 
of brain mass and the occurrence of silent stroke (4). In 
our study, another group of patients who are determined 
homocysteine concentration had vascular dementia as a 
consequence of ischemic stroke. At group with vascular 
dementia hyperhomocysteinemia was present in 62% 
(81.4% men and 39.1% women). According to our re-
sults in the group of patients with vascular dementia, the 
average homocysteine concentration was 20.39 μmol / L. 
Homocysteine in the group of patients with vascular de-
mentia was signifi cantly higher than in the group with 
ischemic stroke and control group (Table 1). According 
to Mann-Whitney test for α = 5%, a signifi cant diff e-
rence between concentrations of homocysteine in the 
acute phase of ischemic stroke and vascular dementia.
Using the same test for α = 5%, a signifi cant diff erence 
between concentrations of homocysteine in the post-
acute phase of ischemic stroke and concentrations of 
homocysteine in vascular dementia. Comparing the re-
sults showed signifi cant diff erences between the average 
concentrations of homocysteine with vascular dementia 
group and control group (p < 0.05) (Table 3). In the gro-
up of patients with vascular dementia, 52% (26 patients) 
had one extensive stroke, 32% (16 patients) two, and 
16% (8 patients), many small ischemic focus without is-
chemic stroke (Figure 3). We got signifi cant correlation 
(Spearman correlation test) between the number of stro-
kes and concentrations of homocysteine in the serum 
of patients with vascular dementia. Th e results of our 
study showed that with increasing number of attacks 
increased concentrations of homocysteine what can 
lead to evolution of vascular dementia aft er ischemic 
stroke. Our results shown that more males has hyperho-
mocysteinemia in relation to females, so they have move 
prevalence for developing new ischemic stroke or vas-
cular dementia. If homocysteine concentration increa-
ses above 14 μmol/L increased the risk for Alzheimer's 
disease or vascular dementia for 4.6 times higher than 
in patients in who has concentration of homocysteine 
is less than 11 μmol/L (24). According to our results, 
homoysteine concentration increasing from acute to 
post-acute phase at patients with ischemic stroke and 
patients with vascular dementia have higher concentra-
tion of homocysteine then patients with ischemic stroke.
Conclusion
Th e homocysteine could be an independent risk factor 
for development of cerebrovascular disease. Th e po-
ssible limitation of of our study are limited number of 
patients and we have not informations about concen-
tration of homocysteine before ischemic brain stro-
ke or vascular dementia. Hyperhomocysteinemia is 
present in about 30% (44% men and 13% females) of 
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patients with ischemic stroke and in about 62% of pa-
tients with vascular dementia (81.4% men and 39.1% 
women). Th e concentration of homocysteine increases 
during 14 days of hospital treatment in comparison of 
homocysteine concentration 24-48 hours aft er ische-
mic stroke. Th e patients with elevated concentration 
of homocysteine aft er stroke have longer hospitalizati-
on than patients with reference value of homocysteine. 
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